Skip to main content
Innoviva, Inc. logo

Innoviva, Inc. — Investor Relations & Filings

Ticker · INVA ISIN · US45781M1018 LEI · 549300ACOX4QTBES6535 US Financial and insurance activities
Open in API
Filings indexed 1,226 across all filing types
Latest filing 2026-05-18 Board/Management Inform…
Country US United States of America
Listing US INVA

About Innoviva, Inc.

https://www.inva.com/

Innoviva, Inc. is a diversified holding company that manages a portfolio of royalty-generating assets and operates a commercial-stage biopharmaceutical platform. The company's core royalty business is centered on respiratory therapies, providing a stable cash flow. Through its subsidiary, Innoviva Specialty Therapeutics, it focuses on developing and commercializing innovative treatments for patients in critical care and with infectious diseases. Innoviva's strategy involves leveraging its financial assets to invest in healthcare opportunities with high unmet medical needs, aiming to advance differentiated therapies and build a diverse portfolio of healthcare assets.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 91% confidence The document is a Form 8-K current report filed with the SEC, specifically describing the resignation of two board members and the election/appointment of a new director along with her compensation arrangements. This fits the definition of a Board/Management Information filing (announcement of changes in the company’s board of directors).
2026-05-18 English
8-K - Innoviva, Inc. (0001080014) (Filer)
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K “Current Report” covering Item 5.07, which is the submission of matters to a vote of security holders. It lists the detailed vote tallies for director elections, advisory votes on executive compensation, auditor ratification, and plan approval at the Annual Meeting. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (Code: DVA).
2026-05-04 English
SCHEDULE 13G/A - Innoviva, Inc. (0001080014) (Subject)
Major Shareholding Notification
2026-03-27 English
8-K - INNOVIVA, INC. (0001080014) (Filer)
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 25, 2026, reporting the results of operations and financial condition for the quarter ended December 31, 2025. It references a press release (Exhibit 99.1) containing the financial results. The text explicitly states that the information is being furnished and is not considered "filed" for certain legal purposes, which is typical for earnings releases. The document length is 3474 characters, which is relatively short and mainly serves as an announcement of the earnings results rather than a full detailed report. Therefore, this document is best classified as an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights only.
2026-02-25 English
10-K - INNOVIVA, INC. (0001080014) (Filer)
Annual Report FY 2025
2026-02-25 English
4 - INNOVIVA, INC. (0001080014) (Filer)
Director's Dealing
2026-02-24 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.